CN114746440B - 新型多肽复合物 - Google Patents

新型多肽复合物 Download PDF

Info

Publication number
CN114746440B
CN114746440B CN202180006946.7A CN202180006946A CN114746440B CN 114746440 B CN114746440 B CN 114746440B CN 202180006946 A CN202180006946 A CN 202180006946A CN 114746440 B CN114746440 B CN 114746440B
Authority
CN
China
Prior art keywords
chain
obscurin
seq
sequence
mutations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180006946.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN114746440A (zh
Inventor
应华
胡齐悦
张玲
毛浪勇
石金平
黎婷婷
赖炜明
覃千山
金薪盛
陶维康
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN114746440A publication Critical patent/CN114746440A/zh
Application granted granted Critical
Publication of CN114746440B publication Critical patent/CN114746440B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180006946.7A 2020-01-09 2021-01-08 新型多肽复合物 Active CN114746440B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010020878 2020-01-09
CN2020100208787 2020-01-09
PCT/CN2021/070832 WO2021139758A1 (zh) 2020-01-09 2021-01-08 新型多肽复合物

Publications (2)

Publication Number Publication Date
CN114746440A CN114746440A (zh) 2022-07-12
CN114746440B true CN114746440B (zh) 2024-11-15

Family

ID=76787741

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180006946.7A Active CN114746440B (zh) 2020-01-09 2021-01-08 新型多肽复合物

Country Status (9)

Country Link
US (1) US20230120270A1 (https=)
EP (1) EP4089111A4 (https=)
JP (1) JP7773981B2 (https=)
KR (1) KR20220123072A (https=)
CN (1) CN114746440B (https=)
AU (1) AU2021205561A1 (https=)
CA (1) CA3164979A1 (https=)
TW (1) TWI878430B (https=)
WO (1) WO2021139758A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3981788A4 (en) 2019-06-04 2023-03-22 Jiangsu Hengrui Medicine Co., Ltd. ANTIBODY CAPABLE OF BINDING THYMIC STROMAL LYMPHOPOIETIN AND ITS USE
MX2023006596A (es) * 2020-12-03 2023-06-19 Jiangsu Hengrui Pharmaceuticals Co Ltd Composicion farmaceutica de anticuerpo anti-tslp y uso de la misma.
TW202317635A (zh) * 2021-07-14 2023-05-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｈｇｆｒ和ｅｇｆｒ的抗原結合分子及其醫藥用途
WO2023147784A1 (zh) 2022-02-07 2023-08-10 江苏恒瑞医药股份有限公司 特异性结合psma和cd3的抗原结合分子及其医药用途
CN118660910A (zh) 2022-03-14 2024-09-17 江苏恒瑞医药股份有限公司 特异性结合gprc5d和cd3的抗原结合分子及其医药用途
TW202405015A (zh) * 2022-04-11 2024-02-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ２８的抗原結合分子及其醫藥用途
TW202413416A (zh) * 2022-04-11 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｅｇｆｒ和ｃｄ２８的抗原結合分子及其醫藥用途
EP4545564A4 (en) * 2022-06-23 2026-01-14 Jiangsu Hengrui Pharmaceuticals Co Ltd Antigen-binding molecule specifically binding to DLL3 and CD3, and its pharmaceutical use
TW202413437A (zh) 2022-08-05 2024-04-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｇｕｃｙ２ｃ和ｃｄ３的抗原結合分子及其醫藥用途
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
CN121712807A (zh) 2023-08-31 2026-03-20 江苏恒瑞医药股份有限公司 Ctla4/tigit结合蛋白及其医药用途
WO2025082377A1 (zh) * 2023-10-17 2025-04-24 江苏恒瑞医药股份有限公司 一种抗tslp抗体的药物组合物及其用途
WO2025106278A1 (en) 2023-11-17 2025-05-22 Mersana Therapeutics, Inc. Treatment of cancer using b7-h4-targeted antibody-drug conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601830A (zh) * 2015-12-18 2018-09-28 比奥根Ma公司 双特异性抗体平台

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5889151A (en) 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2007062037A2 (en) * 2005-11-21 2007-05-31 Laboratoires Serono Sa Compositions and methods of producing hybrid antigen binding molecules and uses thereof
AU2006333077A1 (en) 2005-12-15 2007-07-12 Becton, Dickinson And Company Diagnosis of sepsis
AU2008247649A1 (en) 2007-05-01 2008-11-13 University Of Miami Transcriptomic biomarkers for individual risk assessment in new onset heart failure
WO2012142159A2 (en) * 2011-04-11 2012-10-18 The Brigham And Women's Hospital, Inc Structural mutations in titin cause dilated cardiomyopathy
WO2014014796A1 (en) * 2012-07-18 2014-01-23 Eli Lilly And Company Multi-specific igg-(fab)2 constructs containing t-cell receptor constant domains
CN104619715B (zh) 2012-09-14 2018-06-05 弗·哈夫曼-拉罗切有限公司 包含至少两个不同实体的分子的生产和选择方法及其用途
ES2936810T3 (es) 2014-05-16 2023-03-22 Pfizer Anticuerpos biespecíficos con interfaces CH1-CL de ingeniería
CN117843810A (zh) 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108601830A (zh) * 2015-12-18 2018-09-28 比奥根Ma公司 双特异性抗体平台

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The Crystal Structure of the Human Titin: Obscurin Complex Reveals a Conserved yet Specific Muscle M-Band Zipper Module;Stefano Pernigo;J. Mol. Biol.;第427卷(第4期);第718–736页 *

Also Published As

Publication number Publication date
EP4089111A4 (en) 2023-10-04
KR20220123072A (ko) 2022-09-05
CA3164979A1 (en) 2021-07-15
JP7773981B2 (ja) 2025-11-20
JP2023509212A (ja) 2023-03-07
US20230120270A1 (en) 2023-04-20
WO2021139758A1 (zh) 2021-07-15
TWI878430B (zh) 2025-04-01
TW202128770A (zh) 2021-08-01
CN114746440A (zh) 2022-07-12
EP4089111A1 (en) 2022-11-16
AU2021205561A1 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
CN114746440B (zh) 新型多肽复合物
US20260022166A1 (en) Antibody capable of binding to thymic stromal lymphopoietin and use therof
CN112625136B (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
KR102662387B1 (ko) B7-h3 항체, 이의 항원-결합 단편 및 이의 의학적 용도
CN107614529B (zh) Pd-l1抗体、其抗原结合片段及其医药用途
CN111744013B (zh) 抗tigit抗体联合pd-1抑制剂治疗疾病的方法和药物组合
CN104271602B (zh) 双特异性抗体
CN110914304B (zh) Cd96抗体、其抗原结合片段及医药用途
CN112513089A (zh) 抗cd73抗体、其抗原结合片段及应用
CN112513090A (zh) 结合人il-4r的抗体、其抗原结合片段及其医药用途
CN109983032B (zh) Tim-3抗体、其抗原结合片段及医药用途
KR102709785B1 (ko) Ｉｌ－５ 항체, 이의 항원 결합 단편 및 이의 의학적 적용
WO2022105772A1 (zh) 针对冠状病毒具有中和活性的双特异性抗体及其用途
EP4339213A1 (en) Antigen-binding molecule
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
EP4671276A1 (en) ANTIBODY BANK CONTAINING A COMMON LIGHT CHAIN, ITS PREPARATION METHOD AND ITS USE
RU2847355C1 (ru) Новый полипептидный комплекс
HK40076302A (en) New polypeptide complex
HK40076302B (zh) 新型多肽复合物
CN117343168A (zh) 冠状病毒结合分子及医药用途
HK40045560A (en) Anti-cd73 antibody, antigen-binding fragment thereof and application thereof
HK40045558A (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof
HK40045558B (en) Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40076302

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant